Product image of Levosimendan Kalceks (Levosimendan) supplied by GNH India

Levosimendan Kalceks

Active Ingredient:
Levosimendan
Origin:
EU

Levosimendan Kalceks (Levosimendan)

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer / K‑ATP channel opener presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure and cardiogenic shock, providing inotropic support and vasodilation to improve cardiac output in hospitalized patients.

GNH India supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, ensuring quality and regulatory conformity across EU and global markets through reliable logistics.

Manufacturer / TM Owner

Kalceks

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Levosimendan is used in acute cardiac conditions where enhanced contractility and vasodilation are required.
  • Acute decompensated heart failure: increases cardiac output and relieves symptoms of congestion in hospitalized patients.
  • Cardiogenic shock: provides rapid inotropic support and systemic vasodilation to stabilize hemodynamics.
  • Severe left ventricular failure: enhances stroke volume without raising intracellular calcium, improving tissue perfusion.
  • Post‑cardiac surgery low‑output syndrome: supports myocardial contractility during early postoperative period.

How It Works

  • Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting myocardial contractility without raising intracellular calcium concentrations. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous dilation. The combined inotropic and vasodilatory actions improve cardiac output while reducing preload and afterload. Levosimendan is metabolized to an active long‑lasting metabolite that sustains these effects after the infusion is stopped.

Side Effects

Levosimendan may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects

  • Hypotension: drop in blood pressure, especially during loading dose.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Flushing: transient skin warmth and redness.

Serious or Rare Side Effects

  • Severe hypotension: profound blood pressure fall requiring intervention.
  • Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
  • Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.

Precautions & Warnings

  • When using Levosimendan, clinicians should observe several safety measures.
  • Blood pressure monitoring: observe for hypotension, especially during initiation.
  • Cardiac rhythm surveillance: watch for arrhythmias, particularly ventricular ectopy.
  • Dose adjustment: consider reduced dosing in severe hepatic impairment.
  • Caution in hypotensive patients: avoid rapid infusion rates.
  • Avoid in severe aortic stenosis: risk of excessive vasodilation.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels and risk of toxicity.
  • Concurrent use with other vasodilators (e.g., nitroglycerin): can cause severe hypotension.
  • Co‑administration with other inotropes (e.g., dobutamine): may lead to excessive cardiac stimulation.

Moderate Interactions (Monitor Closely)

  • Diuretics: may amplify volume depletion and hypotension.
  • Beta‑blockers: may blunt desired inotropic effect, requiring dose titration.
  • ACE inhibitors or ARBs: combined effect on blood pressure may need monitoring.

Frequently Asked Questions

Levosimendan Kalceks is indicated for the treatment of acute decompensated heart failure and cardiogenic shock in hospitalized patients. It provides inotropic support and vasodilation to improve cardiac output and relieve symptoms of low‑output states.

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances myocardial contractility without raising intracellular calcium levels. At the same time it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing arterial and venous dilation that reduces cardiac workload.

The dosing regimen for Levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, severity of heart failure, and response to therapy. Typical protocols involve a loading infusion followed by a maintenance infusion, but exact rates and durations are individualized.

Safety data for Levosimendan in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required) and import documentation.

The most common alternative is dobutamine, a β‑adrenergic agonist. Unlike dobutamine, Levosimendan enhances contractility without increasing intracellular calcium and also provides vasodilation through potassium‑channel opening. This dual action can result in lower myocardial oxygen consumption, but both agents require careful blood‑pressure monitoring.

Levosimendan Kalceks should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken. Before use, inspect the vial for particulate matter and ensure the container is within the expiry date.

Levosimendan is given as an intravenous infusion. After reconstitution according to the label, a loading dose may be administered over 10 minutes, followed by a continuous maintenance infusion. The infusion rate is adjusted based on haemodynamic response and tolerability.

The most serious adverse events include severe hypotension, ventricular arrhythmias, and myocardial ischemia. Patients should be closely monitored for blood‑pressure drops, rhythm disturbances, and signs of chest pain or ECG changes during and after the infusion.

Levosimendan is contraindicated in patients with severe hypotension, uncontrolled arrhythmias, or critical aortic stenosis. Caution is also advised in individuals with significant hepatic impairment or those receiving other potent vasodilators.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levosimendan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT